Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Co-administration of PPV23 and IIV4 Vaccines
NCT04559204Phase 4Completed
- Sponsor
- China National Biotec Group
- Start
- Sep 2020
- Primary completion
- Nov 2020
- Modality
- Split/Subunit Vaccines, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of 23-valent pneumococcal polysaccharide vaccine, influenza virus quadrivalent inactivated vaccine in influenza, Pneumococcal pneumonia (PP), sponsored by China National Biotec Group. Started Sep 2020; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccineinfluenza virus quadrivalent inactivated vaccine
03
Conditions
influenzaPneumococcal pneumonia (PP)
Beyond the preview
Go deeper on NCT04559204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04559204.